BCG/M smegmatis vector based live recombinant vaccine (Finlay)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug NameBCG/M smegmatis vector based live recombinant vaccine (Finlay)

Drug Alias Namerecombinant Mycobacterium smegmatis vaccine (Finlay)live recombinant BCG vaccine (Finlay)

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine +[4]

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsTuberculosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCuba

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesFinlay Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFinlay Institute

Active IndicationsN/A

Inactive IndicationsTuberculosis

Other Information

ATC CodeN/A